These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8883697)

  • 21. [From symptom to therapy: clinical reasoning].
    Reinhart WH
    Praxis (Bern 1994); 2002 Nov; 91(46):1981-5. PubMed ID: 12476604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The quest for an optimal alpha.
    Miller J; Ulrich R
    PLoS One; 2019; 14(1):e0208631. PubMed ID: 30601826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA microarrays: vital statistics.
    Tilstone C
    Nature; 2003 Aug; 424(6949):610-2. PubMed ID: 12904757
    [No Abstract]   [Full Text] [Related]  

  • 24. Using evaluations of diagnostic tests: understanding their limitations and making the most of available evidence.
    Deeks JJ
    Ann Oncol; 1999 Jul; 10(7):761-8. PubMed ID: 10470421
    [No Abstract]   [Full Text] [Related]  

  • 25. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The problem of multiple testing.
    Sainani KL
    PM R; 2009 Dec; 1(12):1098-103. PubMed ID: 20006317
    [No Abstract]   [Full Text] [Related]  

  • 27. An investigation of new toxicity test method performance in validation studies: 1. Toxicity test methods that have predictive capacity no greater than chance.
    Bruner LH; Carr GJ; Harbell JW; Curren RD
    Hum Exp Toxicol; 2002 Jun; 21(6):305-12. PubMed ID: 12195934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of diagnostic or screening procedures. Validity of tests, sensitivity, specificity, predictive values. Definition and indications for mass screening].
    Durand-Zaleski I; Bastuji-Garin S
    Rev Prat; 2000 May; 50(10):1155-8. PubMed ID: 10905104
    [No Abstract]   [Full Text] [Related]  

  • 29. False discovery rate, sensitivity and sample size for microarray studies.
    Pawitan Y; Michiels S; Koscielny S; Gusnanto A; Ploner A
    Bioinformatics; 2005 Jul; 21(13):3017-24. PubMed ID: 15840707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An application of mathematical models for decision making to the selection of policies on testing for drug use.
    Correa H; Woods T
    Int J Addict; 1991 Jun; 26(6):697-712. PubMed ID: 1757173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and analysis of qualitative collaborative studies: minimum collaborative program.
    McClure FD
    J Assoc Off Anal Chem; 1990; 73(6):953-60. PubMed ID: 2289928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of statistics when examining lifetime studies in rodents to detect carcinogenicity.
    Salsburg DS
    J Toxicol Environ Health; 1977 Nov; 3(4):611-28. PubMed ID: 592429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Number needed to misdiagnose: a measure of diagnostic test effectiveness.
    Habibzadeh F; Yadollahie M
    Epidemiology; 2013 Jan; 24(1):170. PubMed ID: 23232619
    [No Abstract]   [Full Text] [Related]  

  • 34. Redressing the power and effect of significance. A new approach to an old problem: teaching statistics to nursing students.
    Taylor S; Muncer S
    Nurse Educ Today; 2000 Jul; 20(5):358-64. PubMed ID: 10895117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposed method to determine the decision level for radioactivity measurements.
    Rigaud D
    Health Phys; 2003 Aug; 85(2):140-9. PubMed ID: 12938960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Screening: an appealing but problematic concept].
    Lagerlund M; Zackrisson S
    Lakartidningen; 2013 Mar 20-26; 110(12):628-30. PubMed ID: 23614209
    [No Abstract]   [Full Text] [Related]  

  • 38. Establishing equivalence of two treatments and sample size requirements in matched-pairs design.
    Nam JM
    Biometrics; 1997 Dec; 53(4):1422-30. PubMed ID: 9423257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding significance testing.
    Sidebotham D
    Anaesthesia; 2021 Dec; 76(12):1659-1664. PubMed ID: 34546578
    [No Abstract]   [Full Text] [Related]  

  • 40. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.